文献速递糖尿病

血浆小RNA谱揭示与糖耐量各阶段早期β细胞功能障碍相关的三miRNA特征

Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages.
PubMed 文献 · Diabetologia · 2026-06-06

该横断面研究对发现队列78人(NGT 23、IGT 22、2型糖尿病33)和验证队列158人(非糖尿病71、2型糖尿病87)进行血浆小RNA测序,识别出11个在三组间差异表达的miRNA,并聚焦miR-34a-5p、miR-1306-5p和miR-335-5p组成的三miRNA特征。该特征与β细胞速率敏感性相关,联合年龄和负荷后1小时血糖的LASSO模型可辨别RS值(发现队列Spearman ρ=0.43,p<0.05;验证队列ρ=0.23,p<0.05)。

要点

  • 三miRNA特征(miR-34a-5p、miR-1306-5p、miR-335-5p)与早期β细胞功能障碍相关。
  • 联合年龄和1小时负荷后血糖的LASSO模型可估计β细胞速率敏感性。
  • 以基础血糖替代1小时负荷后血糖后模型在发现队列仍显著,验证队列未达显著。

核心结论

  • 三miRNA特征联合简单临床参数是早期β细胞功能障碍和2型糖尿病进展的有前景的生物标志物,需在更多队列中进一步验证。

研究设计与样本

  • 横断面研究,发现队列78人(NGT 23、IGT 22、2型糖尿病33),验证队列158人(非糖尿病71、2型糖尿病87),均行OGTT和/或MMT并检测血糖、胰岛素和C肽。
  • 采用小RNA测序分析血浆RNA,DESeq2比较糖耐量组间差异,线性回归分析miRNA丰度与临床代谢指标关联,ddPCR验证选定miRNA,LASSO模型选择可估计β细胞速率敏感性的生物标志物特征。

主要发现

  • 发现队列中识别出11个在三组糖耐量间差异表达的miRNA。
  • 三miRNA特征(miR-34a-5p、miR-1306-5p、miR-335-5p)与β细胞速率敏感性相关。
  • 联合年龄和1小时负荷后血糖的LASSO模型可辨别RS值,发现队列Spearman ρ=0.43(p<0.05),验证队列ρ=0.23(p<0.05)。
  • 以基础血糖替代1小时负荷后血糖后,模型在发现队列仍显著(Spearman ρ=0.46,p<0.05),验证队列关联未达显著(Spearman ρ=0.15,p=0.061)。

临床怎么用

  • 该三miRNA特征联合年龄和负荷后血糖可能辅助评估早期β细胞功能障碍,但尚未达到临床常规应用标准。

局限性

  • 研究为横断面设计,无法推断因果关系。
  • 验证队列中替代模型关联未达统计学显著(p=0.061)。
  • 结论需在更多独立队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes mellitus is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable circulating biomarkers are currently available to track this decline. As microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs reflect in vivo beta cell function in living donors. METHODS: We conducted a cross-sectional study on two independent cohorts: a discovery cohort comprising 78 individuals with different levels of glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT) and 33 with type 2 diabetes] and a validation cohort comprising 158 individuals (71 non-diabetic individuals and 87 with type 2 diabetes) who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. We profiled plasma RNA by small RNA sequencing, and analysed differences between glucose tolerance groups using DESeq2. We used linear regression analyses to determine the association between miRNA abundance and clinical and metabolic measures. We validated selected miRNAs using droplet digital PCR (ddPCR). Finally, we specified a set of features that were used as an input for a LASSO model to select a biomarker signature that was able to estimate beta cell rate sensitivity (RS) values as a measure of beta cell function. RESULTS: We identified 11 miRNAs that were differentially expressed across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNA signature (miR-34a-5p, miR-1306-5p and miR-335-5p) that correlated with beta cell RS, which is an early indicator of insulin secretory impairment. We incorporated this panel of selected miRNAs with age and 1 h post-load glucose into a LASSO regression model that enabled discrimination of RS values (Spearman's ρ=0.43, p<0.05). We also confirmed model performance in an additional cohort of 71 non-diabetic individuals and 87 individuals with type 2 diabetes (Spearman's ρ=0.23, p<0.05). To provide proof of concept for potential clinical use, we substituted basal glucose for 1 h post-load glucose while retaining miRNA levels and age; this adaptation preserved the significance of the model in the discovery cohort (Spearman's ρ=0.46, p<0.05), and showed an interesting, but not significant, association in the validation cohort (Spearman's ρ=0.15, p=0.061). CONCLUSIONS/INTERPRETATION: This three-miRNA signature combined with simple clinical parameters constitutes a promising biomarker for early beta cell dysfunction and type 2 diabetes progression that deserves further validation in additional cohorts.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Aiello E, Grieco GE, Brunetti M, et al. Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages. Diabetologia. 2026. PMID: 42251203. doi:10.1007/s00125-026-06766-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。